Table 2.
Antiviral combinations during follow-up.
| Antiviral therapy | Number of patients (%) | Mean duration, years (range) |
| NA only, total | 23/53 (43) | 4.2 (2.2–6.0) |
| Entecavir | 10/23 (44) | 4.4 (1.0–8.2) |
| Entecavir mono | 7/10 (70) | 3.8 (1.0–7.2) |
| Entecavir + Lamivudin | 1/10 (10) | |
| Entecavir + Adefovir | 0/10 (0) | |
| Tenofovir | 15/23 (65) | 2.2 (0.3–8.2) |
| Tenofovir mono | 12/15 (80) | |
| Tenofovir + Entecavir | 2/15 (13) | |
| Tenofovir + Lamivudin | 1/15 (7) | |
| Tenofovir + Entecavir + Lamivudin | 0/15 (0) | |
| Tenofovir + Adefovir | 0/15 (0) | |
| Lamivudin | 2/23 (9) | 6.0 (5.0–7.0) |
| Lamivudin mono | 0/23 (0) | |
| IFNα-based, total (%) | 23/53 (43) | 2.6 (0.0–14.1) |
| IFNα-mono | 1/23 (4) | |
| Combination with NA | 22/23 (96) | |
| Entecavir | 5/22 (23) | |
| Entecavir + Lamivudin | 1/22 (5) | |
| Tenofovir | 11/22 (50) | |
| Tenofovir + Entecavir | 3/22 (14) | |
| Tenofovir + Lamivudin | 1/22 (5) | |
| Tenofovir + Lamivudin + Adefovir | 1/22 (5) | |
| Lamivudin | 0/22 |
IFNα = interferon alpha, mono = monotherapy, NA = nucleos(t)ide analogues.